In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes.
Antimicrob Agents Chemother
; 66(2): e0216521, 2022 02 15.
Article
em En
| MEDLINE
| ID: mdl-34930028
ABSTRACT
Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial currently in phase III clinical trials. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 µg/mL, respectively. Given gepotidacin's in vitro activity against the anaerobic isolates tested, further study is warranted to better understand the utility of gepotidacin in the treatment of infections caused by clinically relevant anaerobic organisms.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Compostos Heterocíclicos com 3 Anéis
/
Acenaftenos
Idioma:
En
Revista:
Antimicrob Agents Chemother
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos